SCHEMBL22200711

SCHEMBL22200711

CSc1ncc2nc(-c3ccc(NSCc4ccccc4)c(F)c3)c(=O)n(C(C)C)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 2/20 0.41
CYP1A2 P05177 15/20 0.41
USP2 O75604 11/20 0.41
CYP3A4 P08684 9/20 0.41
MAPK1 P28482 8/20 0.41
CYP2C9 P11712 7/20 0.41
CYP2C19 P33261 7/20 0.41
MAPT P10636 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
HSD17B10 Q99714 10/20 0.37
ALDH1A1 P00352 10/20 0.37
MEN1 O00255 8/20 0.37
KMT2A Q03164 8/20 0.37
CASP1 P29466 7/20 0.37
CASP7 P55210 6/20 0.37
HIF1A Q16665 6/20 0.37
LMNA P02545 4/20 0.37
TSHR P16473 3/20 0.37
RECQL P46063 2/20 0.37
CYP2D6 P10635 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200338 0.90 ERN1 (0.41) ERN1CYP1A2USP2CYP3A4MAPK1
SCHEMBL22190959 0.85 ERN1 (0.56) ERN1CYP1A2USP2CYP3A4MAPK1
SCHEMBL29357948 0.85 ERN1 (0.56) ERN1CYP1A2USP2CYP3A4MAPK1
SCHEMBL22200731 0.85 ERN1 (0.46) ERN1CYP1A2USP2CYP3A4MAPK1
SCHEMBL22200546 0.84 ERN1 (0.42) ERN1CYP1A2USP2CYP3A4MAPK1
SCHEMBL22200603 0.83 ERN1 (0.43) ERN1CYP1A2USP2CYP3A4MAPK1
SCHEMBL22200345 0.80 ERN1 (0.53) ERN1CYP1A2USP2CYP3A4MAPK1
SCHEMBL22200635 0.80 ERN1 (0.39) ERN1CYP1A2USP2CYP3A4MAPK1
SCHEMBL22200566 0.78 ERN1 (0.40) ERN1MAPTRXFP1TSHR
SCHEMBL22190962 0.78 CYP1A2 (0.42) ERN1CYP1A2USP2CYP3A4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed